Bionote

Fluorescence immunoassay analyzer for veterinary clinics with cumulative global sales approaching about 25,000 units; it runs biomarker tests for canine, feline and equine cardiac, inflammatory, pancreatic, coagulation, hormone and kidney conditions.

Urinalysis analyzer that checks 15 chemistry and 16 sediment parameters in canine and feline urine in about four minutes on one unit; launched in the U.S. in February 2026.

Modular in-clinic chemistry analyzer whose central unit runs chemistry, urine chemistry and electrolyte tests and accepts up to three add-on modules; launched in the U.S. in July 2026.

Technology co-developed with the Korea Disease Control and Prevention Agency covering antibodies specific to an mpox virus membrane protein, hybridoma cell lines producing them and a rapid antigen test kit; patent registration was completed in August 2026.

U.S. subsidiary established in 2019 that sells Vcheck analyzers and tests to U.S. veterinary clinics from Big Lake, Minnesota.

The U.S. subsidiary launched Vcheck U, a urinalysis analyzer that runs urine chemistry and sediment analysis on one unit.

The U.S. subsidiary launched Vcheck C10, a modular chemistry analyzer whose test range expands with add-on modules, and began selling it through authorized distributors.

Completed patent registration for core mpox rapid diagnostic technology co-developed with the Korea Disease Control and Prevention Agency; the company plans to apply it to its diagnostic kit range.

Reported preliminary first-half 2026 consolidated revenue of KRW 68.9 billion and operating profit of KRW 14.8 billion, up about 13% and 34% from a year earlier.